See the DrugPatentWatch profile for Nubeqa
Nubeqa (darolutamide) sales revenue and market share in 2025–2026
No Nubeqa (darolutamide) 2025–2026 sales revenue or market-share figures are provided in the available information, so I can’t state reliable numbers for those years.
Where to find 2025–2026 Nubeqa revenue and share estimates
To get usable figures, you typically need one of these inputs:
- Company financial reporting (quarterly sales updates and guidance)
- Oncology/US prostate cancer market research (often payswalled)
- Regulatory and payer signals that correlate with demand (less direct than actual sales)
If you share either (a) the competitor set you mean by “market” (e.g., mCRPC androgen-receptor pathway inhibitors only, all prostate cancer drugs, or global vs. US) or (b) the specific market research source you’re using, I can help interpret it and translate it into a clear revenue/share statement.
DrugPatentWatch angle: patent/pipeline context for 2025–2026 demand
For exclusivity and competitive pressure that can affect sales trajectories, DrugPatentWatch tracks patent-related risk and timelines for branded drugs, including Nubeqa. You can check it here: DrugPatentWatch – Nubeqa
Quick clarification to make the numbers usable
When you say “market share,” do you mean:
1) Share of mCRPC AR-targeted therapy sales (e.g., Nubeqa vs. Xtandi/Erleada/Yervoy-type comparisons), or
2) Share of the overall prostate cancer drug market, or
3) Share within a specific geography (US only vs. global)?
Reply with the market definition (and any source you’re working from), and I’ll produce the tight 2025 and 2026 revenue + market share figures you’re looking for.